State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical, University of Macau, Macao, China.
Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai 519000, China.
Molecules. 2023 Jul 27;28(15):5678. doi: 10.3390/molecules28155678.
Napabucasin (also known as BBI608) is a natural naphthoquinone originally identified as a cancer cell stemness inhibitor. Accumulated in vitro and in vivo evidence demonstrated that napabucasin showed significant anticancer effects in various types of cancers. Napabucasin inhibits cancer cell proliferation, induces apoptosis and cell cycle arrest, and suppresses metastasis and relapse. Such anticancer activities of napabucasin mainly rely on the inhibition of cancer stemness by targeting signal transducer and activator of transcription 3 (STAT3) and its related gene inhibition. However, several novel molecular targets for napabucasin, such as NAD(P)H:quinone oxidoreductase 1 (NQO1) and thioredoxin reductase 1 (TrxR1), have been reported. Napabucasin represents a promising anticancer lead for multiple cancers. In this mini review, the anticancer potential and the molecular mechanism of napabucasin will be briefly highlighted.
那柏西沙司(也称为 BBI608)是一种天然萘醌,最初被鉴定为一种癌细胞干性抑制剂。体外和体内积累的证据表明,那柏西沙司在各种类型的癌症中表现出显著的抗癌作用。那柏西沙司抑制癌细胞增殖,诱导细胞凋亡和细胞周期停滞,并抑制转移和复发。那柏西沙司的这种抗癌活性主要依赖于通过靶向信号转导子和转录激活子 3(STAT3)及其相关基因抑制来抑制癌症干性。然而,已经报道了那柏西沙司的几个新的分子靶点,如 NAD(P)H:醌氧化还原酶 1(NQO1)和硫氧还蛋白还原酶 1(TrxR1)。那柏西沙司代表了多种癌症有前途的抗癌先导化合物。在这个迷你综述中,将简要强调那柏西沙司的抗癌潜力和分子机制。